Sio Gene Therapies Inc. Quarterly Operating Income (Loss) in USD from Q4 2014 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Sio Gene Therapies Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2014 to Q4 2022.
  • Sio Gene Therapies Inc. Operating Income (Loss) for the quarter ending December 31, 2022 was -$4.02M, a 84.2% increase year-over-year.
  • Sio Gene Therapies Inc. Operating Income (Loss) for the twelve months ending December 31, 2022 was -$28.5M, a 53.8% increase year-over-year.
  • Sio Gene Therapies Inc. annual Operating Income (Loss) for 2021 was -$71.6M, a 119% decline from 2020.
  • Sio Gene Therapies Inc. annual Operating Income (Loss) for 2020 was -$32.6M, a 54.8% increase from 2019.
  • Sio Gene Therapies Inc. annual Operating Income (Loss) for 2019 was -$72.2M, a 44% increase from 2018.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 -$28.5M -$4.02M +$21.4M +84.2% Oct 1, 2022 Dec 31, 2022 10-Q 2023-02-14
Q3 2022 -$50M -$3.08M +$18.2M +85.5% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$68.1M -$8.41M +$3.49M +29.3% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-11
Q1 2022 -$71.6M -$13M -$9.8M -303% Jan 1, 2022 Mar 31, 2022 10-K 2022-06-14
Q4 2021 -$61.8M -$25.5M -$14.8M -138% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 -$47.1M -$21.2M -$11.1M -110% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$36M -$11.9M -$3.33M -38.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$32.6M -$3.24M +$13.1M +80.2% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-14
Q4 2020 -$45.8M -$10.7M +$3.34M +23.8% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-11
Q3 2020 -$49.1M -$10.1M +$3.63M +26.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$52.7M -$8.56M +$19.5M +69.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$72.2M -$16.4M -$7.23M -79.1% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-09
Q4 2019 -$65M -$14M +$20.2M +59% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 -$85.2M -$13.8M +$20M +59.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$105M -$28M +$23.8M +45.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$129M -$9.14M +$16.2M +64% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-10
Q4 2018 -$145M -$34.2M +$23.6M +40.8% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 -$169M -$33.7M +$36.9M +52.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$206M -$51.8M +$14.9M +22.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$221M -$25.4M +$29.3M +53.6% Jan 1, 2018 Mar 31, 2018 10-K 2019-06-11
Q4 2017 -$250M -$57.9M -$9.91M -20.7% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-07
Q3 2017 -$240M -$70.7M -$29.2M -70.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$211M -$66.7M -$28.8M -76.1% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$182M -$54.6M -$24M -78.5% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-11
Q4 2016 -$158M -$48M +$14.6M +23.3% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-09
Q3 2016 -$173M -$41.5M -$26.4M -174% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 -$146M -$37.9M -$13M -52.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 -$133M -$30.6M Jan 1, 2016 Mar 31, 2016 10-K 2018-06-11
Q4 2015 -$62.6M -$51.8M -481% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-14
Q3 2015 -$15.1M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 -$24.9M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q4 2014 -$10.8M Nov 1, 2014 Dec 31, 2014 10-Q 2016-02-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.